Drug intelligence / Profile preview

clorazepate

Development stage: Approved
Lead developer: Recordati
Modality: Small Molecules
Administration: Oral

Overview

Clorazepate is a benzodiazepine medication primarily used for the treatment of anxiety disorders, partial seizures, and symptoms associated with acute alcohol withdrawal. It functions as a prodrug, undergoing rapid decarboxylation in the stomach to form its active metabolite, nordiazepam (desmethyldiazepam). This active metabolite then exerts its therapeutic effects by enhancing the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors in the central nervous system, resulting in anxiolytic, anticonvulsant, sedative, hypnotic, and skeletal muscle relaxant properties. It is administered orally.

Brand names: TranxeneGen-XeneTranxene SDTranxene T-TabTranxiliumNovo-Clopate
Other names: clorazepate dipotassium

Targets

TSPO (Translocator Protein (18 kDa))GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on clorazepate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clorazepate.

Explore the full profile